A review of the known MTA-cooperative PRMT5 inhibitors
RSC Advances · 2024 · 14 (53) · 39653-39691
DOI: 10.1039/d4ra05497k ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift RSC Advances, 2024. Verfasst von Mei Hu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University 1-1 Xiangling Road Luzhou Sichuan 646000 People's Republic of…. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Southwest Medical University.
Abstract (Originalsprache)
Protein arginine methyltransferase 5 (PRMT5) represents a novel epigenetic anti-tumour target with significant clinical potential, and has attracted considerable interest from the academic research community and the pharmaceutical industry.
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University 1-1 Xiangling Road Luzhou Sichuan 646000 People's Republic of China 86487165@qq.com.
ORCID-Profile: Xiang Chen
Förderung
- Southwest Medical University
Zitieren
APA
Hu, M., & Chen, X. (2024). A review of the known MTA-cooperative PRMT5 inhibitors. RSC Advances, 14(53), 39653-39691. https://doi.org/10.1039/d4ra05497k
Vancouver
Hu M, Chen X. A review of the known MTA-cooperative PRMT5 inhibitors. RSC Advances. 2024;14(53):39653-39691. doi:10.1039/d4ra05497k
BibTeX
@article{Hu2024,
author = {Hu, Mei and Chen, Xiang},
title = {A review of the known MTA-cooperative PRMT5 inhibitors},
journal = {RSC Advances},
year = {2024},
volume = {14},
number = {53},
pages = {39653--39691},
doi = {10.1039/d4ra05497k}
}
EUVIMED